drugset / Trial / NCT00564941

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

NCT00564941

Phase 4 Completed 309 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overload

Timeline

Start
2007-12
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferasirox Unknown